Literature DB >> 21147820

Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy.

Tain-Yen Hsia1, Jeremy M Ringewald, Robert E Stroud, Geoffrey A Forbus, Scott M Bradley, Wendy K Chung, Francis G Spinale.   

Abstract

AIMS: The left ventricular phenotype of idiopathic dilated cardiomyopathy (DCM) can appear similar in paediatric and adult patients. However, the aetiology of paediatric DCM is usually idiopathic, and often leads an aggressive clinical course. A structural underpinning of DCM is extracellular matrix changes, which are determined by a balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). This study tested the hypothesis that different MMP/TIMP profiles occur in paediatric and adult DCM patients. METHODS AND
RESULTS: Left ventricular samples from paediatric (age 9 ± 5 years; n = 10) and adult (age 62 ± 3 years; n = 20) DCM (at time of transplant) were subjected to an MMP/TIMP multiplex array and immunoassay in order to measure the MMP subclasses; collagenases (MMP-8, -13), gelatinases (MMP-2, -9), stromelysin/matrilysin (MMP-3, -7), membrane type (MT1-MMP), as well as for the four known TIMPs. MMP-8 and -9 levels increased by over 150% (P < 0.05), whereas MMP-3 and -7 levels decreased by over 30% (P < 0.05) in paediatric DCM when compared with adult DCM. TIMP-1 and -2 levels increased two-fold (P < 0.05), but TIMP-3 fell by 41% (P < 0.05) in paediatric DCM. Myocardial levels of specific interleukins (IL-1beta, IL-2, IL-8) were increased by approximately 50% in paediatric DCM.
CONCLUSIONS: These unique findings demonstrated that a specific MMP/TIMP profile occurs in paediatric DCM when compared with adult DCM, and that local cytokine induction may contribute to this process. These distinct differences in the determinants of myocardial matrix structure and function may contribute to the natural history of DCM in children.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21147820      PMCID: PMC3041467          DOI: 10.1093/eurjhf/hfq184

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  33 in total

1.  Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy.

Authors:  M L Coker; J L Zellner; A J Crumbley; F G Spinale
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

2.  Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.

Authors:  Muzahir H Tayebjee; Gregory Y H Lip; Andrew D Blann; Robert J Macfadyen
Journal:  Thromb Res       Date:  2005       Impact factor: 3.944

3.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.

Authors:  F G Spinale; M L Coker; S R Krombach; R Mukherjee; H Hallak; W V Houck; M J Clair; S B Kribbs; L L Johnson; J T Peterson; M R Zile
Journal:  Circ Res       Date:  1999-08-20       Impact factor: 17.367

4.  Multiplexed analysis of human cytokines by use of the FlowMetrix system.

Authors:  K G Oliver; J R Kettman; R J Fulton
Journal:  Clin Chem       Date:  1998-09       Impact factor: 8.327

5.  Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

Authors:  C V Thomas; M L Coker; J L Zellner; J R Handy; A J Crumbley; F G Spinale
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

6.  Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links.

Authors:  Z Gunja-Smith; A R Morales; R Romanelli; J F Woessner
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

7.  Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts.

Authors:  Joshua D Lovelock; Andrew H Baker; Feng Gao; Jing-Fei Dong; Angela L Bergeron; Willie McPheat; Natarajan Sivasubramanian; Douglas L Mann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-02       Impact factor: 4.733

8.  Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry.

Authors:  J H McElmurray; R Mukherjee; R B New; A C Sampson; M K King; J W Hendrick; A Goldberg; T J Peterson; H Hallak; M R Zile; F G Spinale
Journal:  J Pharmacol Exp Ther       Date:  1999-11       Impact factor: 4.030

9.  Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.

Authors:  Zamaneh Kassiri; Gavin Y Oudit; Otto Sanchez; Fayez Dawood; Fazilat F Mohammed; Robert K Nuttall; Dylan R Edwards; Peter P Liu; Peter H Backx; Rama Khokha
Journal:  Circ Res       Date:  2005-07-21       Impact factor: 17.367

10.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.

Authors:  Y Y Li; A M Feldman; Y Sun; C F McTiernan
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

View more
  3 in total

1.  Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy.

Authors:  Heiner Latus; Kerstin Gummel; Karin Klingel; Axel Moysich; Markus Khalil; Nona Mazhari; Juergen Bauer; Reinhard Kandolf; Dietmar Schranz; Christian Apitz
Journal:  J Cardiovasc Magn Reson       Date:  2015-05-15       Impact factor: 5.364

2.  Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection.

Authors:  Hao Chen; Donghang Zheng; Jeff Abbott; Liying Liu; Mee Y Bartee; Maureen Long; Jennifer Davids; Jennifer Williams; Heinz Feldmann; James Strong; Katrina R Grau; Scott Tibbetts; Colin Macaulay; Grant McFadden; Robert Thoburn; David A Lomas; Francis G Spinale; Herbert W Virgin; Alexandra Lucas
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

3.  Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model.

Authors:  Vishnu Chintalgattu; Joanne Greenberg; Shivani Singh; Venice Chiueh; Amy Gilbert; Jason W O'Neill; Stephen Smith; Simon Jackson; Aarif Y Khakoo; TaeWeon Lee
Journal:  Pharmacol Res Perspect       Date:  2018-11-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.